RT Journal Article
SR Electronic
T1 Stool banking for fecal microbiota transplantation: methods and operations at a large stool bank
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.03.20187583
DO 10.1101/2020.09.03.20187583
A1 Chen, Justin
A1 Zaman, Amanda
A1 Ramakrishna, Bharat
A1 ,
A1 Olesen, Scott W.
YR 2020
UL http://medrxiv.org/content/early/2020/09/09/2020.09.03.20187583.abstract
AB Objectives Fecal microbiota transplantation (FMT) is a recommended therapy for recurrent Clostridioides difficile infection and is being investigated as a potential therapy for dozens of microbiome-mediated indications. Stool banks centralize FMT donor screening and FMT material preparation with the goal of improving the safety, quality, convenience, and accessibility of FMT material. Although there are published consensuses on donor screening guidelines, there are few reports about the implementation of those guidelines in functioning stool banks.Methods To help inform consensus standards with data gathered from real-world settings and, in turn, to improve patient care, here we describe the general methodology used in 2018 by OpenBiome, a large stool bank, and its outputs in that year.Results In 2018, the stool bank received 7,536 stool donations from 210 donors, a daily average of 20.6 donations, and processed 4,271 of those donations into FMT preparations. The median time a screened and enrolled stool donor actively donated stool was 5.8 months. The median time between the manufacture of an FMT preparation and its shipment to a hospital or physician was 8.9 months. Half of the stool bank’s partner hospitals and physicians ordered an average of 0.75 or fewer FMT preparations per month.Conclusions Further knowledge sharing should help inform refinements of stool banking guidelines and best practices.Competing Interest StatementDr. Allegretti is a consultant for Finch Therapeutics, Artugen Therapeutics, and Merck & Co. Carolyn Edelstein's spouse is an employee of and owns shares in Finch Therapeutics. Dr. Fischer serves on a Data Safety Monitoring Board for Rebiotix, Inc. Dr. Ramakrishna is a former employee of Finch Therapeutics.Funding StatementNo external funding was received for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was conducted as part of study protocol 1280272 approved by New England Independent Review Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data underlying the analyses are available in the Supplemental Material.